Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/121955
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Safety and tolerability of bacteriophage therapy for chronic rhinosinusitis due to staphylococcus aureus
Author: Ooi, M.
Drilling, A.
Morales, S.
Fong, S.
Moraitis, S.
MacIas-Valle, L.
Vreugde, S.
Psaltis, A.
Wormald, P.
Citation: JAMA Otolaryngology-Head and Neck Surgery, 2019; 145(8):723-729
Publisher: American Medical Association
Issue Date: 2019
ISSN: 2168-6181
2168-619X
Statement of
Responsibility: 
Mian Li Ooi, Amanda Jane Drilling, Sandra Morales, Stephanie Fong, Sophia Moraitis, Luis Macias-Valle, Sarah Vreugde, Alkis James Psaltis, Peter-JohnWormald
Abstract: Importance: Staphylococcus aureus infections are associated with recalcitrant chronic rhinosinusitis (CRS). The emerging threat of multidrug-resistant S aureus infections has revived interest in bacteriophage (phage) therapy. Objective: To investigate the safety, tolerability, and preliminary efficacy of ascending multiple intranasal doses of investigational phage cocktail AB-SA01 in patients with recalcitrant CRS due to S aureus. Design, Setting, and Participants: This phase 1, first-in-humans, open-label clinical trial of multiple ascending doses was conducted at a single tertiary referral center from December 1, 2015, through September 30, 2016, with follow-up completed on December 31, 2016. Patients with recalcitrant CRS (aged 18-70 years) in whom surgical and medical treatment had failed and who had positive S aureus cultures sensitive to AB-SA01 were recruited. Findings were analyzed from February 2 through August 31, 2017. Interventions: Three patient cohorts (3 patients/cohort) received serial doses of twice-daily intranasal irrigations with AB-SA01 at a concentration of 3 × 108 plaque-forming units (PFU) for 7 days (cohort 1), 3 × 108 PFU for 14 days (cohort 2), and 3 × 109 PFU for 14 days (cohort 3). Main Outcomes and Measures: The primary study outcome was the safety and tolerability of intranasal AB-SA01. Safety observations included vital signs, physical examinations, clinical laboratory test results, and adverse events. The secondary outcome was preliminary efficacy assessed by comparing pretreatment and posttreatment microbiology results, disease-relevant endoscopic Lund-Kennedy Scores, and symptom scores using a visual analog scale and Sino-Nasal Outcome Test-22. Results: All 9 participants (4 men and 5 women; median age, 45 years [interquartile range, 41.0-71.5 years]) completed the trial. Intranasal phage treatment was well tolerated, with no serious adverse events or deaths reported in any of the 3 cohorts. No change in vital signs occurred before and 0.5 and 2.0 hours after administration of AB-SA01 and at the exit visit. No changes in biochemistry were found except for 1 participant in cohort 3 who showed a decrease in blood bicarbonate levels on exit visit, with normal results of physical examination and vital signs. All biochemistry values were normalized 8 days later. No changes in temperature were recorded before, during, or after treatment. Six adverse effects were reported in 6 participants; all were classified as mild treatment-emergent adverse effects and resolved by the end of the study. Preliminary efficacy results indicated favorable outcomes across all cohorts, with 2 of 9 patients showing clinical and microbiological evidence of eradication of infection. Conclusions and Relevance: Intranasal irrigation with AB-SA01 of doses to 3 × 109 PFU for 14 days was safe and well tolerated, with promising preliminary efficacy observations. Phage therapy could be an alternative to antibiotics for patients with CRS.
Rights: © 2019 American Medical Association. All rights reserved.
RMID: 0030119589
DOI: 10.1001/jamaoto.2019.1191
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.